These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26905802)

  • 21. Design of highly potent HIV fusion inhibitors based on artificial peptide sequences.
    Shi W; Cai L; Lu L; Wang C; Wang K; Xu L; Zhang S; Han H; Jiang X; Zheng B; Jiang S; Liu K
    Chem Commun (Camb); 2012 Dec; 48(94):11579-81. PubMed ID: 23093045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.
    Haro I; Gómara MJ; Galatola R; Domènech O; Prat J; Girona V; Busquets MA
    Biochim Biophys Acta; 2011 Jun; 1808(6):1567-73. PubMed ID: 21377446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.
    Xiang J; McLinden JH; Kaufman TM; Mohr EL; Bhattarai N; Chang Q; Stapleton JT
    Virology; 2012 Aug; 430(1):53-62. PubMed ID: 22608061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41.
    Hrin R; Montgomery DL; Wang F; Condra JH; An Z; Strohl WR; Bianchi E; Pessi A; Joyce JG; Wang YJ
    AIDS Res Hum Retroviruses; 2008 Dec; 24(12):1537-44. PubMed ID: 19102685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion.
    Dams G; Van Acker K; Gustin E; Vereycken I; Bunkens L; Holemans P; Smeulders L; Clayton R; Ohagen A; Hertogs K
    J Biomol Screen; 2007 Sep; 12(6):865-74. PubMed ID: 17644771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of GBV-C infection in HIV-1 infected patients.
    Canducci F; Uberti Foppa C; Boeri E; Racca S; Gallotta G; Grasso MA; Calori G; Lazzarin A; Clementi M
    J Biol Regul Homeost Agents; 2003; 17(2):191-4. PubMed ID: 14518722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia.
    Souza IE; Allen JB; Xiang J; Klinzman D; Diaz R; Zhang S; Chaloner K; Zdunek D; Hess G; Williams CF; Benning L; Stapleton JT
    J Clin Microbiol; 2006 Sep; 44(9):3105-13. PubMed ID: 16954234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of hepatitis G virus (GB virus C) on the prognosis of HIV-infected women.
    Campos AF; Tengan FM; Silva SA; Levi JE
    Int J STD AIDS; 2011 Apr; 22(4):209-13. PubMed ID: 21515753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
    Kliger Y; Shai Y
    J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mode of interaction between the HIV-1-neutralizing monoclonal antibody 2F5 and its epitope.
    Fiebig U; Schmolke M; Eschricht M; Kurth R; Denner J
    AIDS; 2009 May; 23(8):887-95. PubMed ID: 19414989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models.
    Sánchez-Martín MJ; Busquets MA; Girona V; Haro I; Alsina MA; Pujol M
    Biochim Biophys Acta; 2011 Sep; 1808(9):2178-88. PubMed ID: 21672514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV type-1 entry inhibitors with a new mode of action.
    Fink RC; Roschek B; Alberte RS
    Antivir Chem Chemother; 2009; 19(6):243-55. PubMed ID: 19641233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.
    Sánchez-Martín MJ; Urbán P; Pujol M; Haro I; Alsina MA; Busquets MA
    Chemphyschem; 2011 Oct; 12(15):2816-22. PubMed ID: 21905195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infection with GB virus C and reduced mortality among HIV-infected patients.
    Tillmann HL; Heiken H; Knapik-Botor A; Heringlake S; Ockenga J; Wilber JC; Goergen B; Detmer J; McMorrow M; Stoll M; Schmidt RE; Manns MP
    N Engl J Med; 2001 Sep; 345(10):715-24. PubMed ID: 11547740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
    Barbouche R; Decroly E; Kieny MP; Fenouillet E
    Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.
    Cocklin S; Gopi H; Querido B; Nimmagadda M; Kuriakose S; Cicala C; Ajith S; Baxter S; Arthos J; Martín-García J; Chaiken IM
    J Virol; 2007 Apr; 81(7):3645-8. PubMed ID: 17251295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
    Eckert DM; Kim PS
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different susceptibility of human immunodeficiency virus type 1 to Env gp41-derived synthetic peptides corresponding to the C-terminal heptad repeat region.
    N A PI; Li GM; Warachit J; Iwabu Y; Tsuji S; Auwanit W; Yamamoto D; Goto T; Hayashi Y; Kiso Y; Ikuta K
    Microbes Infect; 2005 Mar; 7(3):356-64. PubMed ID: 15780966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.